What to Expect During Treatment Consultation Youll meet with a healthcare provider to assess your needs and determine the right dosage and frequency for your treatment
Barbalace MC, Talotta R, Rapisarda F, DAmico V, Lagan M, Malaguti M et al (2025) Unlocking the Power of the Mediterranean Diet: Two in One-Dual Benefits for Rheumatic and Thyroid Autoimmune Diseases
Discard the prepared syringe
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
Digestive changes, including constipation, often ease as the body adjusts to a steady dose, though timing varies by person
Safety Guide Wegovy (semaglutide 2.4 mg) can generally be taken safely after gallbladder removal, as cholecystectomy is not listed as a contraindication by the MHRA
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
